Elvina Almuradova: Doxorubicin with Trabectedin show promising results for patients with leiomyosarcoma
Elvina Almuradova, Medical Oncologist Ambassador at European School of Oncology, shared on LinkedIn:
“New findings published in the NEJM show promising results for patients with leiomyosarcoma! Combining doxorubicin with trabectedin improved outcomes significantly:
**Median Overall Survival:** 33 months with doxorubicin-trabectedin vs. 24 months with doxorubicin alone (HR 0.65)
**Progression-Free Survival:** 12 months vs. 6 months (HR 0.37)
While there were more adverse events with the combination, these results suggest that adding trabectedin could be a game-changer in treatment.”
Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma | NEJM
Authors: Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, Nelly Firmin, Pascaline Boudou-Rouquette, François Bertucci, Valérie Lebrun-Ly, Isabelle Ray-Coquard, Elsa Kalbacher, Emmanuelle Bompas, Olivier Collard, Nicolas Isambert, Cécile Guillemet, Maria Rios, Axel Le Cesne, Corinne Balleyguier, Baptiste Archambaud, Florence Duffaud,
Source: Elvina Almuradova/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023